Between new approaches and bio-technological innovations.
Scholars, researchers and ophthalmologists from all over the world gathered in Seattle (USA) this year for the event that is undoubtedly the 'showcase' for research in ophthalmology: the ARVO congress (1-5 May).
In a world that is changing ever more rapidly and in which the very concept of 'quality of health' is evolving, becoming ever more articulated and complex, there is much room for ideas and insights coming from public and private scientific research laboratories.
We offer a thoughtful and, we hope, stimulating review of the posters presented by the SIFI R&D Group in which the variety and complexity of the most current ophthalmological research areas is reflected.
We begin with the themes of "Drug delivery, in which modern nanotechnology may have important new applications, especially in the posterior segment of the eye.
"Calixarene-based nanoformulation for ocular delivery of curcumin: in vitro and in vivo anti-inflammatory activity evaluation."
Calix ARVO 2016 poster
Also in the field 'Drug delivery'but aimed in this case at the anterior segment the focus should be on xanthan-based gel, which improves the ocular pharmacokinetics of active ingredients with antibacterial and anti-inflammatory action.
"Ocular distribution of new Hydrogel based on Xanthan Gum vs Eyedrops containing Netilmicin and Dexamethasone."
NETILDEX GEL PK ARVO 2016
The application of the OCT technology then allows the ability of the gel to remain on the ocular surface to be assessed.
"Measurement of the retention time of different ophthalmic formulations with ultra-high resolution Optical Coherence Tomography."
Poster Netildex ARVO_2016
The use of molecules anti-VEGF has undoubtedly marked a revolution in the treatment of maculopathies, but how much more can be done in the area of supportive therapies to be combined with intravitreal anti-angiogenic treatments?
"Effect of a new dietary supplement formula on the activity and expression of pro-inflammatory genes in vitro."
 ARVO 1270 poster
"Individual components of a nutraceutical formula synergistically contribute to the effect on COX-2 and iNos activity and expression."
ARVO 1460 poster
On the front of the search for a medical therapy for the Acanthamoeba keratitis, the ODAK project continues its development with pre-clinical phase data aimed at selecting the safest and most effective concentration for use in clinical trials.
"Ocular tolerability assessment of PHMB (Polyhexanide) 0.8%, 0.25% and 0.08% ophthalmic solutions in rabbits."
ODAK_Poster ARVO 2016
We also anticipate news of the conclusion of Phase I of the clinical trial, on which we will update you shortly.
Finally in the field of antibiotic therapy, very interesting in the treatment of fungal-based eye infections are the results of a study in vitro e in vivo in a model of keratitis from Candidaaimed at evaluating the efficacy of a fixed combination of three antibiotics.
"Efficacy of a fixed combination of three antibiotics against Candida species."
Colbiocin ARVO 2016 poster
Dr. Carmelo Chines
Direttore responsabile
English 
Italian